2-chloro-4-[5-[(Z)-[3-[2-(4-methylanilino)-2-oxoethyl]-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]furan-2-yl]benzoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-chloro-4-[5-[(Z)-[3-[2-(4-methylanilino)-2-oxoethyl]-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]furan-2-yl]benzoic acid
• 化学式: C₂₄H₁₇ClN₂O₆S
• 分子量: 496.9
• InChiKey: FSWYRLDCYUORIK-JAIQZWGSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  142
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
  申请人：Yeda Research and Development Co. Ltd

  公开号：US10144778B2

  公开（公告）日：2018-12-04

  A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

  本发明提供了一种药物组合物，该药物组合物包含一种活性剂，可降低个体的全身免疫抑制水平，用于治疗中枢神经系统的疾病、失调、状况或损伤，但不包括自身免疫性神经炎症疾病--复发性多发性硬化症（RRMS）。该药物组合物通过至少两个疗程的剂量方案给药，每个疗程依次包括一个治疗疗程和一个间歇疗程。
• Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the CNS
  申请人：Yeda Research and Development Co. Ltd

  公开号：US11492405B2

  公开（公告）日：2022-11-08

  The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

  本说明书公开了一种药物组合物，该药物组合物包含一种活性剂，可降低个体的全身免疫抑制水平，用于治疗中枢神经系统的疾病、紊乱、病症或损伤。 该药物组合物通过一个剂量方案给药，该剂量方案包括至少一个疗程，每个疗程依次包括一个治疗疗程和一个非治疗间隔疗程。
• REDUCING SYSTEMIC REGULATORY T CELL LEVELS OR ACTIVITY FOR TREATMENT OF DISEASE AND INJURY OF THE CNS
  申请人：Yeda Research and Development Co. Ltd

  公开号：EP3509636A1

  公开（公告）日：2019-07-17
• Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain
  申请人：Mackerell Alexander

  公开号：US20070099970A1

  公开（公告）日：2007-05-03

  Small molecular-weight non-peptidic compounds block Lck SH2 domain-dependent interactions. The inhibitors omit phosphotyrosine (pY) or related moieties.
• Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
  申请人：Mackerell Alexander

  公开号：US20070196395A1

  公开（公告）日：2007-08-23

  Small molecular-weight non-peptidic compounds block Lck SH2 domain-dependent interactions. The inhibitors omit phosphotyrosine (pY) or related moieties.